Analysts Set Aptose Biosciences Inc. (NASDAQ:APTO) Price Target at $19.80

Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) have earned an average recommendation of “Buy” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $19.80.

APTO has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, March 27th. Piper Sandler restated an “overweight” rating and set a $5.00 price target on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. Finally, StockNews.com raised shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, March 28th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of APTO. Texas Capital Bank Wealth Management Services Inc acquired a new stake in Aptose Biosciences in the fourth quarter worth about $32,000. Annandale Capital LLC increased its stake in Aptose Biosciences by 40.0% during the 3rd quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 21,334 shares during the period. Finally, Sigma Planning Corp bought a new stake in shares of Aptose Biosciences during the 3rd quarter worth about $408,000. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Price Performance

Shares of NASDAQ:APTO opened at $1.23 on Wednesday. The company has a market cap of $19.34 million, a PE ratio of -0.16 and a beta of 1.29. Aptose Biosciences has a fifty-two week low of $1.20 and a fifty-two week high of $8.70. The firm has a 50-day simple moving average of $1.59 and a 200 day simple moving average of $2.13.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its earnings results on Tuesday, March 26th. The biotechnology company reported ($1.44) EPS for the quarter, beating the consensus estimate of ($1.48) by $0.04. As a group, research analysts forecast that Aptose Biosciences will post -3.31 EPS for the current fiscal year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.